Filing Details

Accession Number:
0001209191-17-064045
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-12-05 18:34:09
Reporting Period:
2017-12-01
Accepted Time:
2017-12-05 18:34:09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1652923 Avexis Inc. AVXS Biological Products, (No Disgnostic Substances) (2836) 901038273
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1665859 K. Brian Kaspar C/O Avexis, Inc.
2275 Half Day Road, Suite 200
Bannockburn IL 60015
Chief Scientific Officer Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2017-12-01 300 $91.84 1,826,502 No 4 S Direct
Common Stock Disposition 2017-12-01 1,071 $93.27 1,825,431 No 4 S Direct
Common Stock Disposition 2017-12-01 2,685 $94.14 1,822,746 No 4 S Direct
Common Stock Disposition 2017-12-01 9,810 $95.00 1,812,936 No 4 S Direct
Common Stock Disposition 2017-12-01 1,134 $95.95 1,811,802 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 29, 2017.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.33 to $92.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.53 to $93.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.55 to $94.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.55 to $95.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.55 to $96.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4.